Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | MicroRNA signatures in MDS

Inga Mandac • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, discusses the role of microRNA’s in the pathogenesis of MDS and how impoving our understanding of microRNA will allow for the stratification of patients and provide new potential treatment options for MDS. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Inga Mandac

3:04
Expanding MDS therapy options
Inga Mandac • 5 Mar 2020
1:12
Future MDS treatment options
Inga Mandac • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals